What is the new share repurchase program's size and timeline?

HealthStream's Board approved a $10 million repurchase authorization on March 13, 2026. The program will terminate on the earlier of September 12, 2026, or when the full $10 million is expended. As of the Q2 filing, $4.3 million had been deployed over the first six months, leaving approximately $5.7 million remaining.

How does this authorization compare to the prior program?

The prior authorization, announced November 11, 2025, also was $10 million and was fully depleted by the end of Q1 2026. The new March 2026 program replaces it with identical sizing but an extended expiration date of mid-September 2026 instead of the original schedule.

What execution methods can HealthStream use for these repurchases?

The Company may execute repurchases in the open market pursuant to Rule 10b5-1 trading plans, through privately negotiated transactions, or by other means. This flexibility allows the Company to optimize the timing and method of repurchases based on market conditions.

What was the average price paid for shares repurchased in H1 2026?

Across both the prior and new programs, HealthStream repurchased 432,476 shares for an aggregate $9.3 million in the first half of 2026, averaging $21.50 per share (excluding broker commissions and the 1% Inflation Reduction Act excise tax).

How does the buyback fit with HealthStream's overall capital allocation strategy?

The $10 million repurchase program runs concurrently with HealthStream's quarterly cash dividend of $0.035 per share and strategic investments in platform development and acquisitions. The Company's debt-free balance sheet and $66.7 million in liquid assets support this multi-pronged capital return strategy.

HSTM 8-K Filed 2026-08-03 New authorization

HealthStream authorizes $10M share repurchase program

Board approves new buyback plan effective March 13, 2026; Company has repurchased $4.3M in first half of 2026.

Authorization$10M

Remaining$6M

MechanismRule 10b5-1 plans, open-market

What the filing says

On March 13, 2026, HealthStream Inc.'s Board of Directors approved a new share repurchase program authorizing the Company to repurchase up to $10.0 million of its outstanding common stock. The repurchases may be executed in the open market, including under Rule 10b5-1 plans, through privately negotiated transactions, or by other means. The program will terminate on the earlier of September 12, 2026, or when the maximum dollar amount is exhausted.

During the six months ended June 30, 2026, HealthStream repurchased 209,498 shares of common stock at an aggregate fair value of $4.3 million under this authorization, reflecting an average purchase price of approximately $20.53 per share (excluding broker commissions and the 1% share repurchase excise tax). In the second quarter of 2026 alone, the Company repurchased 90,131 shares at an aggregate fair value of $1.8 million under the program.

This new authorization supersedes a prior program announced on November 11, 2025, which authorized $10.0 million in repurchases and was fully expended by the end of the first quarter of 2026. Under that prior program, the Company repurchased 222,978 shares at an aggregate fair value of $5.0 million. In total, HealthStream repurchased 432,476 shares for $9.3 million during the first six months of 2026 across both programs.

On March 13, 2026, the Company announced a new share repurchase program approved by the Board of Directors under which the Company is authorized to repurchase up to $10.0 million of its outstanding shares of common stock. Pursuant to this authorization, the Company is authorized to make repurchases in the open market, including under Rule 10b5-1 plans, through privately negotiated transactions, or otherwise. — HEALTHSTREAM INC 8-K filing · View on SEC EDGAR →

What this means

HealthStream's $10 million authorization—announced in March 2026 but disclosed in this Q2 earnings filing—represents a modest renewal of the Company's share-repurchase activity. With $4.3 million deployed in the first half of 2026 and approximately $5.7 million remaining under the program, the buyback is progressing at a moderate pace. The average execution price of $20.53 per share and the Company's strong cash position ($66.7 million in cash, equivalents, and marketable securities as of June 30) suggest financial flexibility. This repurchase activity, combined with a quarterly dividend of $0.035 per share, reflects capital return to shareholders while the Company invests in growth initiatives and its hStream platform.

Frequently asked questions

What is the new share repurchase program's size and timeline?: HealthStream's Board approved a $10 million repurchase authorization on March 13, 2026. The program will terminate on the earlier of September 12, 2026, or when the full $10 million is expended. As of the Q2 filing, $4.3 million had been deployed over the first six months, leaving approximately $5.7 million remaining.
How does this authorization compare to the prior program?: The prior authorization, announced November 11, 2025, also was $10 million and was fully depleted by the end of Q1 2026. The new March 2026 program replaces it with identical sizing but an extended expiration date of mid-September 2026 instead of the original schedule.
What execution methods can HealthStream use for these repurchases?: The Company may execute repurchases in the open market pursuant to Rule 10b5-1 trading plans, through privately negotiated transactions, or by other means. This flexibility allows the Company to optimize the timing and method of repurchases based on market conditions.
What was the average price paid for shares repurchased in H1 2026?: Across both the prior and new programs, HealthStream repurchased 432,476 shares for an aggregate $9.3 million in the first half of 2026, averaging $21.50 per share (excluding broker commissions and the 1% Inflation Reduction Act excise tax).
How does the buyback fit with HealthStream's overall capital allocation strategy?: The $10 million repurchase program runs concurrently with HealthStream's quarterly cash dividend of $0.035 per share and strategic investments in platform development and acquisitions. The Company's debt-free balance sheet and $66.7 million in liquid assets support this multi-pronged capital return strategy.

authorization rule-10b5-1 healthcare-tech mid-cap cash-return execution

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.